[1]
|
Altieri, D.C. (1994) Splicing of Effector Cell Protease Receptor-1 mRNA Is Modulated by an Unusual Retained Intron. Biochemistry, 33, 13848-13855.
https://doi.org/10.1021/bi00250a039
|
[2]
|
Cohen, C., Lohmann, C.M., Cotsonis, G., Lawson, D. and Santoianni, R. (2003) (ASCP) Survivin Expression in Ovarian Carcinoma: Correlation with Apoptotic Markers and Prognosis. Modern Pathology, 16, 574-583.
https://doi.org/10.1097/01.MP.0000073868.31297.B0
|
[3]
|
Wheatley, S.P. and McNeish, I.A. (2005) Survivin: A Protein with Dual Roles in Mitosis and Apoptosis. International Review of Cytology, 247, 35-88.
https://doi.org/10.1016/S0074-7696(05)47002-3
|
[4]
|
Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: Enemies within. Science, 281, 1312-1316. https://doi.org/10.1126/science.281.5381.1312
|
[5]
|
Sollberger, G., Strittmatter, G.E., Garstkiewicz, M., Sand, J. and Beer, H.-D. (2014) Caspase-1: The Inflammasome and Beyond. Innate Immunity, 20, 115-125.
https://doi.org/10.1177/1753425913484374
|
[6]
|
Altieri, D.C. (2003) Survivin, Versatile Modulation of Cell Division and Apoptosis in Cancer. Oncogene, 22, 8581-8589. https://doi.org/10.1038/sj.onc.1207113
|
[7]
|
Wang, Z., Fukuda, S. and Pelus, L.M. (2004) Survivin Regulates the p53 Tumor Suppressor Gene Family. Oncogene, 23, 8146-8153.
https://doi.org/10.1038/sj.onc.1207992
|
[8]
|
Sah, N.K., Khan, Z., Khan, G.J. and Bisen, P.S. (2006) Structural, Functional and Therapeutic Biology of Survivin. Cancer Letters, 244, 164-171.
https://doi.org/10.1016/j.canlet.2006.03.007
|
[9]
|
Fortugno, P., Wall, N.R., Giodini, A., O’Connor, D.S., Plescia, J., et al. (2002) Survivin Exists in Immunochemically Distinct Subcellular Pools and Is Involved in Spindle Microtubule Function. Journal of Cell Science, 115, 575-585.
|
[10]
|
Li, F. and Ling, X. (2006) Survivin Study: An Update of “What Is the Next Wave”? Journal of Cellular Physiology, 208, 476-486. https://doi.org/10.1002/jcp.20634
|
[11]
|
Yin, W., Chen, N., Zhang, Y., et al. (2006) Survivin Nuclear Labeling Index: A Superior Biomarker in Superficial Urothelial Carcinoma of Human Urinary Bladder. Modern Pathology, 19, 1487-1497. https://doi.org/10.1038/modpathol.3800675
|
[12]
|
Yildirim, U., Erdem, H., Kayikci, A., Sahin, A.F., Uzunlar, A.K. and Albayrak, A. (2010) Cyclooxygenase-2 and Survivin in Superficial Urothelial Carcinoma of the Bladder and Correlation with Intratumoural Microvessel Density. Journal of International Medical Research, 38, 1689-1699.
https://doi.org/10.1177/147323001003800514
|
[13]
|
Margulis, V., Lotan, Y. and Shariat, S. (2008) Survivin: A Promising Biomarker for Detection and Prognosis of Bladder Cancer. World Journal of Urology, 26, 59-65.
https://doi.org/10.1007/s00345-007-0219-y
|
[14]
|
Jeon, C., Kim, M., Kwak, C., Kim, H.H. and Ku, J.H. (2013) Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis. PLoS One, 8, e76719.
https://doi.org/10.1371/journal.pone.0076719
|
[15]
|
Vriesema, J.L., Poucki, M.H., Kiemeney, L.A. and Witjes, J.A. (2000) Patient Opinion of Urinary Tests versus Flexible Urethra Cystoscopy in Follow-Up Examination for Superficial Bladder Cancer: A Utility Analysis. Urology, 56, 793-797.
https://doi.org/10.1016/S0090-4295(00)00777-9
|
[16]
|
Li, Y., Ma, X., Wu, X., Liu, X. and Liu, L. (2014) Prognostic Significance of Survivin in Breast Cancer: Meta-Analysis. The Breast Journal, 20, 514-524.
https://doi.org/10.1111/tbj.12303
|
[17]
|
Jha, K., Shukla, M. and Pandey, M. (2012) Survivin Expression and Targeting in Breast Cancer. Surgical Oncology, 21, 125-131.
https://doi.org/10.1016/j.suronc.2011.01.001
|
[18]
|
Youssef, N.S., Hewedi, I.H. and Abd Raboh, N.M. (2008) Immunohistochemical Expression of Survivin in Breast Carcinoma: Relationship with Clinicopathological Parameters, Proliferation and Molecular Classification. Journal of the Egyptian National Cancer Institute, 20, 348-357.
|
[19]
|
Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J. and Duffy, M.J. (2006) Survivin Expression in Breast Cancer Predicts Clinical Outcome and Is Associated with HER2, VEGF, Urokinase Plasminogen Activator and PAI-1. Annals of Oncology, 17, 597-604.
https://doi.org/10.1093/annonc/mdj121
|
[20]
|
Li, L., Zhang, X.L., Wang, P. and Liu, Y. (2014) Expression of Survivin in Ameloblastoma and Its Clinical Significance. Shanghai Journal of Stomatology, 23, 481-484.
|
[21]
|
Khan, Z., Tiwari, R.P., Mulherkar, R., Sah, N.K., Prasad, G., Shrivastava, B.R. and Bisen, P.S. (2009) Detection of Survivin and p53 in Human Oral Cancer: Correlation with Clinicopathologic Findings. Head Neck, 31, 1039-1048.
|
[22]
|
Uzawa, T.C.K., Shibahara, T., Yokoe, H., Noma, H. and Tanzawa, H. (2003) Expression of an Inhibitor of Apoptosis, Survivin, in Oral Carcinogenesis. Journal of Dental Research, 82, 607-611. https://doi.org/10.1177/154405910308200807
|
[23]
|
Engels, K., Knauer, S.K., Metzler, D., Simf, C., Struschka, O., Bier, C., Mann, W., Kovács, A.F. and Stauber, R.H. (2007) Dynamic Intracellular Survivin in Oral Squamous Cell Carcinoma: Underlying Molecular Mechanism and Potential as an Early Prognostic Marker. The Journal of Pathology, 211, 532-540.
|
[24]
|
Lo Muzio, L., Pannone, G., Staibano, S., Mignogna, M.D., Rubini, C., Mariggiò, M.A., Procaccini, M., Ferrari, F., De Rosa, G. and Altieri, D.C. (2003) Survivin Expression in Oral Squamous Cell Carcinoma. British Journal of Cancer, 89, 2244-2248.
|
[25]
|
Su, L., Wang, Y., Xiao, M., Lin, Y. and Yu, L. (2010) Up-Regulation of Survivin in Oral Squamous Cell Carcinoma Correlates with Poor Prognosis and Chemoresistance. Oral and Maxillofacial Pathology, 110, 484-491.
|
[26]
|
Kawasaki, H., Toyoda, M., Okuda, H.S.J., Watanabe, I., et al. (2001) Expression of Survivin Correlates with Apoptosis, Proliferation, and Angiogenesis during Human Colorectal Tumorigenesis. American Cancer Society, 91, 2026-2032.
|
[27]
|
Kim, P.J., Plescia, J., Clevers, H., Fearon, E.R. and Altieri, D.C. (2003) Survivin and Molecular Pathogenesis of Colorectal Cancer. The Lancet, 362, 205-209.
|
[28]
|
Sarelaa, A.I., Macadama, R.C., Farmerya, S.M., Markhamb, A.F. and Guilloua, P.J. (2000) Expression of the Antiapoptosis Gene, Survivin, Predicts Death from Recurrent Colorectal Carcinoma. Gut, 46, 645-650. https://doi.org/10.1136/gut.46.5.645
|
[29]
|
Tu, S.P., Cui, J.T., Liston, P., et al. (2004) Gene Therapy for Colon Cancer by Adeno-Associated Viral Vector-Mediated Transfer of Survivin Cys84Ala Mutant. Gastroenterology, 128, 361-375.
|
[30]
|
Yamamotoa, T., Manomeb, Y., Nakamuraa, M. and Tanigawaa, N. (2002) Downregulation of Survivin Expression by Induction of the Effector Cell Protease Receptor-1 Reduces Tumor Growth Potential and Results in an Increased Sensitivity to Anticancer Agents in Human Colon Cancer. European Journal of Cancer, 38, 2316-2324.
|
[31]
|
Kawasaki, H., Altieri, D.C., Lu, C.-D., Toyoda, M., Tenjo, T. and Tanigawa, N. (1998) Inhibition of Apoptosis by Survivin Predicts Shorter Survival Rates in Colorectal Cancer. Cancer Research, 58, 5071-5074.
|
[32]
|
Liguang, Z., Peishu, L., Hongluan, M., Hong, J., Rong, W., Wachtel, M.S. and Frezza, E.E. (2007) Survivin Expression in Ovarian Cancer. Experimental Oncology, 29, 121-125.
|
[33]
|
Chen, L., Liang, L., Yan, X., Liu, N., Gong, L., Pan, S., Lin, F., Zhang, Q., Zhao, H. and Zheng, F. (2013) Survivin Status Affects Prognosis and Chemosensitivity in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 23, 256-263.
https://doi.org/10.1097/IGC.0b013e31827ad2b8
|
[34]
|
Pallares, J., Martínez-Guitarte, J.L., Dolcet, X., Llobet, D., Rue, M., Palacios, J., Prat, J. and Matias-Guiu, X. (2005) Survivin Expression in Endometrial Carcinoma: A Tissue Microarray Study with Correlation with PTEN and STAT-3. International Journal of Gynecological Pathology, 24, 247-253
|
[35]
|
Vanderstraeten, A., Everaert, T., Van Bree, R., et al. (2015) In Vitro Validation of Survivin as Target Tumor-Associated Antigen for Immunotherapy in Uterine Cancer. Journal of Immunotherapy, 38, 239-249.
|
[36]
|
Congmin, G., Mu, Z., Yihui, M. and Hanliang, L. (2006) Survivin—An Attractive Target for RNAi in Non-Hodgkin’s Lymphoma, Daudi Cell Line as a Model. Leukemia & Lymphoma, 47, 1941-1948. https://doi.org/10.1080/10428190600725354
|
[37]
|
He, C., Liu, Z., Ji, J. and Zhu, H. (2015) Prognostic Value of Survivin in Patients with Non-Hodgkin’s Lymphoma: A Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 5847-5854.
|
[38]
|
Xie, Y., Ma, X., Gu, L., Li, H., Chen, L., et al. (2016) Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Scientific Reports, 6, Article No. 29794.
|
[39]
|
Fields, A.C., Cotsonis, G., Sexton, D., Santoianni, R. and Cohen, C. (2004) Survivin Expression in Hepatocellular Carcinoma: Correlation with Proliferation, Prognostic Parameters, and Outcome. Modern Pathology, 17, 1378-1385.
https://doi.org/10.1038/modpathol.3800203
|
[40]
|
Kannangai, R., Wang, J., Liu, Q.Z., Sahin, F. and Torbenson, M. (2005) Survivin Overexpression in Hepatocellular Carcinoma Is Associated with p53 Dysregulation. International Journal of Gastrointestinal Cancer, 35, 53-60.
https://doi.org/10.1385/IJGC:35:1:053
|
[41]
|
Montorsi, M., Maggioni, M., Falleni, M., Pellegrini, C., Donadon, M., Torzilli, G., Santambrogio, R., Spinelli, A., Coggi, G. and Bosari, S.H. (2007) Survivin Gene Expression in Chronic Liver Disease and Hepatocellular Carcinoma. Hepatogastroenterology, 54, 2040-2044.
|
[42]
|
Hasby, E.A. and Mokhtar, M.A. (2010) Survivin Immunohistochemical Expression in Hepatocellular Carcinoma: Correlation with Tumor Differentiation and Proliferation. Arab Journal of Gastroenterology, 11, 141-148.
|
[43]
|
Kami, K., Doi, R., Koizumi, M., Toyoda, E., Mori, T., Ito, D., Fujimoto, K., Wada, M., Miyatake, S. and Imamura, M. (2004) Survivin Expression Is a Prognostic Marker in Pancreatic Cancer Patients. Surgery, 136, 443-448.
https://doi.org/10.1016/j.surg.2004.05.023
|
[44]
|
Waligórska-Stachura, J., Jankowska, A., Wasko, R., Liebert, W., et al. (2012) Survivin Prognostic Tumor Biomarker in Human Neoplasms—Review. Ginekologia Polska, 83, 537-540.
|
[45]
|
Rödel, F., Sprenger, T., Kaina, B., Liersch, T., Rödel, C., Fulda, S. and Hehlgans, S. (2012) Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy. Current Medicinal Chemistry, 19, 3679-3688.
|
[46]
|
Rödel, F., Reichert, S., Sprenger, T., Gaipl, U.S., Mirsch, J., Liersch, T., Fulda, S. and Rödel, C. (2011) The Role of Survivin for Radiation Oncology: Moving beyond Apoptosis Inhibition. Current Medicinal Chemistry, 18, 191-199.
https://doi.org/10.2174/092986711794088362
|
[47]
|
Blanc-Brude, O.P., Mesri, M., Wall, N.R., et al. (2003) Therapeutic Targeting of the Survivin Pathway in Cancer: Initiation of Mitochondrial Apoptosis and Suppression of Tumor-Associated Angiogenesis. Clinical Cancer Research, 9, 2683-2692.
|
[48]
|
Sharma, H., Sen, S., Mathur, M., Bahadur, S. and Singh, N. (2004) Combined Evaluation of Expression of Telomerase, Survivin, and Anti-Apoptotic bcl-2 Family Members in Relation to Loss of Differentiation and Apoptosis in Human Head and Neck Cancers. Head and Neck, 26, 733-740.
|
[49]
|
Khan, Z., Khan, N., Tiwari, R.P., Patro, I.K., Prasad, G.B. and Bisen, P.S. (2010) Down-Regulation of Survivin by Oxaliplatin Diminishes Radioresistance of Head and Neck Squamous Carcinoma Cells. Radiotherapy and Oncology, 96, 267-273.
https://doi.org/10.1016/j.radonc.2010.06.005
|